Santhera Pharmaceuticals Holding AG (SPHDF)
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Sector: Biotechnology
Industry: Biotechnology
Santhera Pharmaceuticals Holding AG
- 1.5%
- 160.9K
- 999.99
Float 10.98M · FMP free float
The cost to borrow SPHDF shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- No fails on record for 16–31 Oct 2026.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 160.9K sh |
| Oct 15, 2026 | 160.6K sh |
| Sep 30, 2026 | 150.8K sh |
| Sep 15, 2026 | 138.7K sh |
| Aug 31, 2026 | 144.9K sh |
A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
FINRA publishes no off-exchange short volume for this symbol.
FINRA's weekly alternative trading system (dark pool) volume for SPHDF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 160,922 SPHDF shares were sold short (1.47% of a 10.98M-share float, 999.99 days to cover).